Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00113321 | Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00453193 | Alemtuzumab and Pentostatin In T-cell Neoplasms | terminated | Phase 2 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00480987 |
| Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) |
| terminated |
| Phase 1 / Phase 2 |
| 27 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Aug 7, 2012 |
| clinicaltrials |
| NCT00509600 | Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00810576 | Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT01222195 | Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00074763 | Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets | terminated | Phase 3 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00443300 | Effectiveness of Protected Environment Rooms for AML and MDS | terminated | — | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00081887 | Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00504985 | Fatigue in Emergency Center Patients | terminated | — | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00513305 | Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia | terminated | Phase 3 | 67 | CephalonINDUSTRY | 2 | Aug 1, 2012 | clinicaltrials |
| NCT00514189 | Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines | terminated | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT01103388 | Rituximab Maintenance After Autologous Transplantation | terminated | Phase 3 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT00843050 | A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 13 | Piramal Enterprises LimitedINDUSTRY | 2 | Jul 27, 2012 | clinicaltrials |
| NCT00127881 | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | terminated | Phase 3 | 76 | Emergent Product Development Seattle LLCINDUSTRY | 5 | Jul 26, 2012 | clinicaltrials |
| NCT01029509 | Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes | terminated | Phase 1 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 23, 2012 | clinicaltrials |
| NCT01645124 | Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)(CYTO-PV) | terminated | Phase 3 | 365 | Consorzio Mario Negri SudOTHER | 1 | Jul 20, 2012 | clinicaltrials |
| NCT00014326 | Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma | terminated | Phase 3 | 204 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 16, 2012 | clinicaltrials |
| NCT00893997 | PR1 Vaccination in Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2012 | clinicaltrials |
| NCT00368121 | EMMA-1 (Erbitux for Multiple Myeloma)(EMMA-1) | terminated | Phase 2 | 13 | Prof. Dr. Andreas EngertOTHER | 1 | Jul 13, 2012 | clinicaltrials |
| NCT00003152 | Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma | terminated | Phase 3 | 469 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Jul 2, 2012 | clinicaltrials |
| NCT00208975 | Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab | terminated | Phase 2 | 15 | Emory UniversityOTHER | 1 | Jun 28, 2012 | clinicaltrials |
| NCT00005595 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease | terminated | Phase 2 | 2 | Northwestern UniversityOTHER | 1 | Jun 11, 2012 | clinicaltrials |
| NCT00151736 | Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 88 | CephalonINDUSTRY | 5 | Jun 11, 2012 | clinicaltrials |
| NCT00004106 | Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome | terminated | Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00005788 | Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome | terminated | Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00005787 | Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 | 3 | Northwestern UniversityOTHER | 1 | Jun 1, 2012 | clinicaltrials |
| NCT00253552 | G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders | terminated | N/A | 4 | OHSU Knight Cancer InstituteOTHER | 1 | May 28, 2012 | clinicaltrials |
| NCT00383097 | Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma(ALDI) | terminated | Phase 1 | 6 | Baylor College of MedicineOTHER | 1 | May 24, 2012 | clinicaltrials |
| NCT00128921 | Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 18 | University of ArkansasOTHER | 1 | Apr 26, 2012 | clinicaltrials |
| NCT00499889 | Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | terminated | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2012 | clinicaltrials |
| NCT00704691 | Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas | terminated | Early Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00515138 | A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant | terminated | Early Phase 1 | 7 | University of California, San FranciscoOTHER | 1 | Apr 12, 2012 | clinicaltrials |
| NCT00171925 | Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I | terminated | Phase 3 | 143 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 11, 2012 | clinicaltrials |
| NCT00366106 | Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma | terminated | Phase 2 | 32 | Accelerated Community Oncology Research NetworkOTHER | 1 | Apr 6, 2012 | clinicaltrials |
| NCT00121186 | S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 3, 2012 | clinicaltrials |
| NCT00827099 | Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 5 | Northside Hospital, Inc.OTHER | 1 | Mar 23, 2012 | clinicaltrials |
| NCT01066468 | Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 13, 2012 | clinicaltrials |
| NCT01546337 | Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome(EPO) | terminated | — | 30 | Rennes University HospitalOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT01053884 | Anidulafungin in Patients With Hematologic Malignancies(ECALTA) | terminated | Phase 2 | 10 | Elisabethinen HospitalOTHER | 1 | Mar 2, 2012 | clinicaltrials |
| NCT00074750 | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | terminated | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT00475332 | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar | terminated | Phase 2 | 2 | University of FloridaOTHER | 1 | Feb 15, 2012 | clinicaltrials |
| NCT00124748 | Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)(TOPS) | terminated | Phase 3 | 476 | Novartis PharmaceuticalsINDUSTRY | 6 | Feb 3, 2012 | clinicaltrials |
| NCT00419081 | Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens | terminated | Phase 2 | 100 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 23, 2012 | clinicaltrials |
| NCT00446303 | A Phase II Study of Maintenance With Azacitidine in MDS Patients | terminated | Phase 2 | 39 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00245128 | Imatinib Mesylate in Treating Patients With Myelofibrosis | terminated | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 13, 2012 | clinicaltrials |
| NCT00432419 | Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation Following Chemotherapy. | terminated | Phase 1 / Phase 2 | 1 | French National Agency for Research on AIDS and Viral HepatitisOTHER_GOV | 1 | Dec 22, 2011 | clinicaltrials |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2011 | clinicaltrials |
| NCT00895297 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia(Dasatinib) | terminated | Phase 2 | 50 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Dec 7, 2011 | clinicaltrials |
| NCT01127542 | RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial(RESPeCT) | terminated | Phase 2 | 1 | The Christie NHS Foundation TrustOTHER | 1 | Dec 5, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2012source: clinicaltrials